Similar articles

Abstract: Although significant progress has been made in the development of novel targeted drugs for the treatment of acute myeloid leukemia (AML) in recent years, chemotherapy still remains the mainstay of treatment and the overall survival is poor in most patients. Here, we demonstrated the antileukemia activity of a novel small molecular compound NL101, which is formed through the modification on bendamustine with a suberanilohydroxamic acid (SAHA) radical. NL101 suppresses the proliferation of myeloid malignancy cells and primary AML cells. It induces DNA damage and caspase 3-mediated apoptosis. A genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) library screen revealed that phosphatase and tensin homologous (PTEN) gene is critical for the regulation of cell survival upon NL101 treatment. The knockout or inhibition of PTEN significantly reduced NL101-induced apoptosis in AML and myelodysplastic syndrome (MDS) cells, accompanied by the activation of protein kinase B (AKT) signaling pathway. The inhibition of mammalian target of rapamycin (mTOR) by rapamycin enhanced the sensitivity of AML cells to NL101-induced cell death. These findings uncover PTEN protein expression as a major determinant of chemosensitivity to NL101 and provide a novel strategy to treat AML with the combination of NL101 and rapamycin.

全基因组CRISPR筛选揭示PTEN基因在急性髓系白血病化疗敏感性中的关键作用

[1]BurnettAK, das GuptaE, KnapperS, et al., 2018. Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. Haematologica, 103(10):1654-1661.

[2]CalimeriT, FerreriAJM, 2017. m-TOR inhibitors and their potential role in haematological malignancies. Br J Haematol, 177(5):684-702.

[3]ContieriB, DuarteBKL, LazariniM, 2020. Updates on DNA methylation modifiers in acute myeloid leukemia. Ann Hematol, 99(4):693-701.

[4]del PesoL, González-GarcíaM, PageC, et al., 1997. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science, 278(5338):687-689.

[5]HouPP, WuC, WangYC, et al., 2017. A genome-wide CRISPR screen identifies genes critical for resistance to FLT3 inhibitor AC220. Cancer Res, 77(16):4402-4413.

[6]JiangH, PritchardJR, WilliamsRT, et al., 2011. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol, 7(2):92-100.

[7]KantarjianHM, KadiaTM, DiNardoCD, et al., 2021. Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach. Cancer, 127(8):1186-1207.

[8]KayserS, LevisMJ, 2018. Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol, 180(4):484-500.

[9]KurataM, RatheSK, BaileyNJ, et al., 2016. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML. Sci Rep, 6:36199.

[10]LeeJH, LiuR, LiJ, et al., 2017. Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis. Nat Commun, 8:949.

[11]LeyTJ, MillerC, DingL, et al., 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 368(22):2059-2074.

[12]LiS, HeX, GanYC, et al., 2021. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma. Theranostics, 11(7):3439-3451.

[13]LiuC, DingHY, LiXX, et al., 2015. A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. EMBO Mol Med, 7(4):438-449.

[14]LiuYF, YangEJ, ZhangBY, et al., 2018. PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A. Cancer Lett, 436:‍28-37.

[15]López-IglesiasAA, HerreroAB, ChesiM, et al., 2017. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. J Hematol Oncol, 10:127.

[16]MahalingamD, MedinaEC, EsquivelJA, et al., 2010. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res, 16(1):141-153.

[17]MakLH, VilarR, WoscholskiR, 2010. Characterisation of the PTEN inhibitor VO-OHpic. J Chem Biol, 3(4):157-163.

[18]MorottiA, PanuzzoC, CrivellaroS, et al., 2015. The role of PTEN in myeloid malignancies. Hematol Rep, 7(4):6027.

[19]NogueiraV, ParkY, ChenCC, et al., 2008. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell, 14(6):458-470.

[20]RuizS, Mayor-RuizC, LafargaV, et al., 2016. A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors. Molecular Cell, 62(2):307-313.

[21]SanjanaNE, ShalemO, ZhangF, 2014. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods, 11(8):783-784.

[22]SayginC, CarrawayHE, 2017. Emerging therapies for acute myeloid leukemia. J Hematol Oncol, 10:93.

[23]ShalemO, SanjanaNE, HartenianE, et al., 2014. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science, 343(6166):84-87.

[24]ShaoF, GaoYB, WangW, et al., 2022. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade. Nat Cancer, 3(10):1192-1210.

[25]SteubeKG, GignacSM, HuZB, et al., 1997. In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1. Leuk Lymphoma, 25(3-4):345-363.

[26]TeacheyDT, GruppSA, BrownVI, 2009. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol, 145(5):569-580.

[27]YamaguchiH, WangHG, 2001. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene, 20(53):7779-7786.

[28]ZhengL, LiangH, ZhangQL, et al., 2022. circPTEN1, a circular RNA generated from PTEN, suppresses cancer progression through inhibition of TGF-‍β/Smad signaling. Mol Cancer, 21:41.

[29]ZhengYH, YangWW, XiaY, et al., 2011. Ras-induced and extracellular signal-regulated kinase 1 and 2 phosphorylation-dependent isomerization of protein tyrosine phosphatase (PTP)‍-PEST by PIN1 promotes FAK dephosphorylation by PTP-PEST. Mol Cell Biol, 31(21):‍4258-4269.

[30]ZhengYH, YangWW, AldapeK, et al., 2013. Epidermal growth factor (EGF)‍-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion. J Biol Chem, 288(44):31488-31495.